1. June, 2017 Company presentation

2. FORWARD-LOOKING STATEMENTS
This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Vicore Pharma’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to, implementation of Vicore Pharma’s strategy and its ability to further grow, risks associated with the development and/or approval of Vicore Pharma’s products candidates, ongoing clinical trials and expected trial results, the ability to commercialize C21, technology changes and new products in Vicore Pharma’s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Vicore Pharma disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 2

3. VICORE PHARMA OVERVIEW (VICO)
Founded in 2000 and based in Gothenburg, Sweden, Vicore Pharma is a global biotech company that develops small molecules that stimulate endogenous healing and repair systems. Vicore Pharma’s business strategy is to lead the development of drugs based on stimulating the AT2 receptor in the Renin-Angiotensin-System. The first-generation drugs will be focused on Orphan diseases.
Financial Highlights
Listed on NASDAQ OMX First North (ticker: VICO)
Market cap: approx. USD 30m (May 2017)
Annual operating costs ~ SEK 12m
Closed SEK 56m (USD 6.2m) directed share issue to institutional investors in February 2017
Lead drug candidate: C21
Agonist which specifically binds the angiotensin II type 2 receptor (AT2R)
Stimulates the AT2R resulting in down stream signalling cascade
Induces endogenous healing and repair systems within the cell
Small molecule
Potential for many disease indications and collaborations
Company Highlights
Lead Drug Candidate: C21
First in class AT2R agonist
Granted Orphan Drug Designation for Idiopathic Pulmonary Fibrosis (IPF) in the EU and USA
Phase II studies to start in for Idiopatic Pulmonary Fibrosis and Diabetic Nephropathy 3

4. UNIVERSITIES ENGAGED IN C21 RESEARCH
Canada
Dalhousie Univ. – Bezuhly (wound healing)
McGill Univ. – Hamel (AD) UK
UCL (PF, Clinical development)
Slovakia
Univ. of Bratislava - Paulis (Vascular)
Sweden
Hallberg et al (Chemistry, MS)
Denmark
Univ. of Odense - Steckelings (Vascular, Stroke, NMO, Signaling)
Steno Clinic, Copenhagen - Rossing (Diabetic nephropathy)
France
INSERM - Nahmias (Cancer)
Univ. of Limogés – Demiot (Pain)
Univ. of Angers – Henrion (
Vascular, immunology)
USA
Univ. of Florida - Sumners (Stroke, PAH)
Univ. of Florida - Katovich (IPF)
Univ. of Virginia - Carey (Renal)
Univ. of Houston - Hussain (Metabolism)
Univ. of Georgia - Fagan (Stroke) –
Univ. of Nebraska - Gao (Cardiac)
CCHMC - Malik (sickle-cell disease)
Univ. of Iowa - Sabharwal (Muscular dystrophy)
Univ. of New York - Rodrigues (Cerebral Malaria)
Johns Hopkins - Neptune (COPD)
Belgium
Univ. of Leuven – Verbrugghe (Aneurysms)
Univ. of Brussels – Brouwers (Central blood pressure)
Italy
Univ. of Padua - Vanderriele (Effects on aldosterone)
Univ. of Milano - Castoldi (Renal)
Germany
Univ. of Regensburg – Castrop (Renal)
Aachen Univ. – Jankowsky (Vasoactive mechanisms)
Brazil
Univ. of Goias – Freiria- Oliveira (high-sodium intake)
Univ. of Sao Paolo – Villela (AT2 receptor mechanisms)
Finland
Univ. of Turku – Scheinin (Clinical Phase I)
Argentina
Univ. of Buenos Aires – Dominici (glucose and insulin)
Spain
Univ. of Madrid – Mateos (Stroke)
Univ. of Santiago de Compostela – Rodriguez (Parkinson)
Clinical development
Preclinical
Turkey
Univ. of Inonu – Ermis (Cardioprotection)
Headquarter
India
BITS, Rajastan – Pandey (diabetic nephropathy)
Australia
Baker Institute, Melbourne- Jandeleit-Dahm (Diabetic complications)
Monash Univ., Melbourne - Denton (gender differences)
China
Chinese Univ. of Hong-Kong –Leong (stem-cells and re-generation)
PLA hospital, Beijing – Liu (pancreas)
Japan
Univ. of Ehime - Horiuchi (Stroke, Diabetes)
Univ. of Yokohama - Uemura (Cancer)
Holland
Univ. of Maastricht - Unger (Spinal cord, Vascular) 4

5. GROWING INTEREST IN C21 RESEARCH
Published items in each year
Citations in each year
Publications and Citations involving C21, Vicore Pharma´s leading drug candidate 5

6. EXAMPLES OF RESEARCH QUOTES ON C21 BENEFITS
“These data suggest that C21 has a beneficial effect on islet cell function and regeneration” Wang et al. Pancreas Mar
“Most notably, C21 reversed pulmonary fibrosis and prevented right ventricular fibrosis” Bruce et al. Br J Pharmacol May
“These findings demonstrate that monotherapy of Compound 21 is protective against the progression of experimental diabetic nephropathy by inhibiting renal oxidative stress, inflammation, and fibrosis” Koulis et al. Hypertension May
“C21 prevented TNFα-induced and HFD-induced vascular inflammation in vitro and in vivo” Sampson et al. Br J Pharmacol, 2016 Feb
“C21 provides direct neuroprotection as well as indirect protection through IL-10” Fouda et al. Eur J Pharmacol, 2017 Mar
“Our data suggest that selective AT2R-stimulation improves functional recovery in experimental spinal cord injury ” Namsolleck
et al. Neurobiology of Disease (2012)
“Our study suggests that AT2 receptor stimulation may be a new therapeutic approach to improve eating disorder associated with dopamine resistance” Nakaouka et al. J Renin Angiotensin Aldosterone Syst Mar 6

7. RAS AND C21 ACTIVATION OF AT2R
Angiotensinogen
Angiotensin I
ACE inhibition
Angiotensin II
C21
AT1- blockers
AT-1 receptor
AT-2 receptor
Protective RAS
Ubiquitously expressed
Pressor action
Salt and water retention
Vascular inflammation
Cardiovascular hypertrophy
Upregulated in response to tissue injury
NO release – vasodilator
Antiproliferative
Antiinflammatory
Antifibrotic
Neuroprotective
Neuroregenerative
C21 specifically binds and activates the AT-2 receptor (Protective RAS) 7

8. MANAGEMENT TEAM Per Jansson, D.D.S CEO
Mr Jansson has held leading positions in the medical industry for more than twenty years. He has managed and successfully grown research-based start-up companies, both clinically and commercially.
Ulrike Steckelings, M.D., Ph.D., CSO
Is Professor of Integrative Pharmacology at University of Southern Denmark, Odense. She has extensive research experience in the fields of the Renin Angiotensin System and the AT2 receptor, and has published numerous articles in peer reviewed journals. She also holds a clinical degree in dermatology.
Johanna Gräns, Ph.D.
Regulatory Affairs Manager
Dr Gräns has a Ph.D and expertise in pharmaceutical metabolism. She has extensive experience in preclinical interpretation and is responsible for producing and refining the regulatory documentation for C21.
Klas Malmberg, M.D.,Ph.D.
Chief Medical Officer
Dr Malmberg has more than 14 years of experience from the pharma industry. Most recently, he was Global Clinical Leader at Roche, where he was responsible for the clinical development of Algetazar with over 40,000 patients. Previous engagements include Astra Zeneca. He is a certified cardiologist.
Dan Isaksson, Ph.D.
CMC Coordinator
Dr Isaksson is an organic chemist and has been working in the biotech industry since  A lot of the R&D work has been around formulation and controlled release of actives from various matrixes, as well as patenting promising new technologies.
Nina Carlén
IR, Communication & Administration
Nina has more than 15 years’ experience of working with marketing and communication in the medical industry. 8

9. PIPELINE
Discovery
Preparation and testing of model compounds
Selection of drug candidates
Pre-clinical development
Phase I
Phase II
Phase III
Idiopathic pulmonary fibrosis (IPF) **
C21
Spinal cord Injury *
Acute Ischemic stroke *
Pulmonary arterial hypertension (PAH)
Renal failure due to Sickle-cell disease *
Currently developed by
academic partners
Orphan indications
Diabetic Nephropathy ***
* See appendix for sample data
** Phase Ila study planned with University College of London
*** Phase Ila study planned with Steno Clinic, Copenhagen
Investigator sponsored Phase II studies likely to be initiated in multiple indications 9

10. Phase IIa Multicenter study
DEVELOPMENT TIMELINE
2017
2018
2019
Tox study - 3 months
Capsule Formulation
Bioequivalence study
Phase Ib – Metabolic profile in obese
Idiopathic Pulmonary Fibrosis (IPF)*
Diabetic Nephropathy**
Acute Ischemic stroke ***
Phase IIa
5 Patients
Phase IIa Multicenter study
Patients
Phase IIa
20 Patients
Phase I
Ongoing
Fully Financed
Planned
* Phase Ila study planned with University College of London
** Phase Ila study planned with Steno Clinic, Copenhagen
*** NIH application pending

11. RECENT KEY MILESTONES January: Started Phase I extension study March:
BioMAP with C21 study shows excellent results on fibrosis
August:
ODD–
IPF (EU)
May:
Start of Phase I studies
February:
NCEs developed and patent application filed
2016
2017
February:
Directed share issue announced
July: Phase I
extension study reported
November: Phase I
MAD completed
June:
Phase I
SAD
completed
January:
ODD –
IPF (USA) 11

12. SCIENTIFIC AND MEDICAL ADVISORS
Björn Dahlöf, MD, PhD,
Associate Professor in CV Prevention
He has practiced general internal medicine at the Sahlgrenska University Hospital for more than 35 years. Dahlöf has a broad experience in cardiovascular research, pharmacology, drug development and clinical trials of all phases. In total Dahlöf have published more than 400 peer reviewed scientific articles. He has taken an active scientific interest with the AT2 receptor for more than 20 years.
Colin Sumners, Ph.D.
Professor & Program Director
Dep. of Physiology & Functional Genomics
University of Florida, Gainesville
Has studied the Renin Angiotensin System for ~40 years. He has extensive experience with regard to angiotensin actions in neural tissues and has published extensively in this area. His current focus is on the protective AT2 receptor in the brain, as a target for stroke- and anti-hypertensive therapeutics.
Anders Ljunggren, B.Pharm
Has been working with cardiovascular projects in the pharmaceutical industry for over 30 years. His main interest is the Renin Angiotensin System (RAS). He has long experience from preclinical and clinical projects involving both ACE-inhibition and angiotensin receptor blockade.
Thomas Unger, M.D., Ph.D.
Professor Emeritus in Pharmacology,
University of Maastricht
CARIM (School for Cardiovascular Diseases) at Maastricht University. He is a world-renowned researcher and authority in the cardiovascular area, with more than 600 published articles. He has taken a special interest in research on the AT2 receptor. Prof. Unger is also a valued speaker at international conferences in the cardiovascular area.
Michael Katovich, Ph.D.,
Professor in Pharmacodynamics,
University of Florida, Gainesville
Has studied the various components of the endocrine renin-angiotensin system (RAS) and their effects on hypertension and associated cardiovascular organ damage. 12

13. LEAD DRUG CANDIDATE: C21 A NOVEL DISEASE MODIFIER

14. C21 FIRST IN CLASS AT2R AGONIST
C21 is a small molecule with beneficial drug profile properties
First non-peptide AT2R agonist
Water soluble
Oral bioavailability 20-30%
t ½ man: 4-6 hours
Highly selective binding to AT2Rs:
Ki AT1R > nM
Ki AT2R = 0,4 nM
C21 mode of action
C21 is an agonist which specifically binds to the angiotensin II type 2receptor (AT2R)
C21 stimulates the AT2R resulting in down stream signalling cascades (see slide 16)
C21 induces endogenous healing and repair systems within the cell
Small molecule
C21 is a small molecule and therapeutically effective being developed for once daily (QD) oral application.
A 48 healthy volunteers phase I study has confirmed C21’s good safety profile as well as beneficial drug properties
No SAEs have been documented in the phase I study
Multiple disease indications
Different scientific groups at universities around the world are executing proprietary preclinical research for Vicore Pharma and as such identifying several disease indication in which C21 can be used. 14

15. C21 PHASE I DATA FINALIZED IN 2016: PROVEN SAFETY MARGIN
Successful completion of phase I dose escalating study with C21
48 healthy subjects in a randomized dose escalating control trial
C21 proved to be safe and well tolerated with no SAEs
Dose limiting toxicity was not reached with the highest dose of 100mg/day
Doses in phase I
NOAEL
HED (mg)
(Based on human 70 kg) 10
700
100 50
0.1
400
Response
Therapeutic range
Toxic dose
Oral
i.p. 70
C21 is safe with no SAEs and with beneficial drug profile properties 15

16. PHASE 1 SAFETY AND METABOLIC PROFILE
The study is done on 16 overweight (BMI and hip/waist ratio <0.9) men where of 8 are given C21 (100 mg, once daily in the clinic) and 8 are given placebo
To evaluate safety, tolerability and biomarkers (insulin/glucose, adiponectin, blood fats) with C21 in a metabolically compromized risk group
Biomarkers could be of interest for future studies within diabetes and metabolism
Top-line results due in July, 2017.
Last-volunteer-out 11 April 2017
IMPROVED MOLECULES
New improved drug molecule patent filed 2017
In 2017 the company designed and synthesized a new set of molecules targeting the AT2-receptor using C21 as a design template
The new compounds will be directed towards disease areas in the cardio-metabolic field
The new patent which is pending opens up the possibility to develop the company’s AT2-receptor technology outside the orphan drug space
The new patents will allow for protection until at least 2037 16

17. C21 IN IDIOPATHIC PULMONARY FIBROSIS

18. WHY A NEW DRUG IN IPF? Huge unmet need for:
Orally available drug with minimal side-effects
Ability to include the whole IPF population and stop disease progression
Ability to reverse already established fibrosis
Ability to improve QoL and substantially prolong life expectancy
Current drugs have unsatisfactory efficacy and AEs
Need for multimodal approach:
Anti-fibrotic effects
Anti-apoptotic effect
Anti-proliferative effect
Improvement of vascular remodelling/antifibrotic vascular effects
Anti-inflammatory effect
Anti-cytokine effect
Median survival years after diagnosis
Incidence rising, prevalence 15-20/
Men > women, mean age 66 at diagnosis
Pathophysiology; “Abnormal wound healing”  fibrosis progressive restriction of lung capacity and oxygenation
Pulmonary Hypertension
Esbriet (pirfenidone) and Ofev (nintedanib) approved, annual sales around USD 700m and USD 500m* respectively, but have limited efficacy and problems with adverse effects
NO CURE 18

19. MULTIMODAL ACTION OF AT2R SIGNALING
Compound 21
cytokines
relaxin
TGF-b
AT1R
AT2R
TGFbRII
AT2R
RXFP1
SHP-1
EGRG-1
PDGF-BB
PP2A
MKP-1
CTGF
NF-kB
JAK/STAT
ERK1/2
MMP2,9 
ATIP
ERK1/2
eNOS
Collagen / ECM NO
Anti-inflammation
Vasodilation
Anti-fibrosis
Anti-proliferation
Green lines: effect of C21
: dimerisation

20. C21 REVERSES DISEASE IN ANIMAL MODELS
Lung Fibrosis
Perivascular Fibrosis
* Significantly different from control
# Significantly different from MCT
$ Significantly different from MCT+C21
Control
MCT
MCT+C21
MCT+C21+PD
MCT+PD
Bruce et al., 2015 Br. J. Pharmacol.172; 20

21. C21 ATTENUATES TGFb EXPRESSION AND LOWERS PULMONARY BLOOD PRESSURE
Right ventricular systolic pressure
Systemic blood pressure
MCT: Monocrotaline
C21: Compound 21
PD: PD (AT2-antagonist)
*p<0.05 compared to control; #<0.05 compared to MCT; $<0.05 compared to MCT+C21
Bruce et al., 2015 Br. J. Pharmacol.172; 21

22. C21: PRECLINICAL EFFICACY STUDIES FIBROSIS
Organ/Tissue
Model
Anti-fibrotic effect/
Collagen reduction
Reference
Heart LV
Coronary ligation, WR, 6w
+ P
Lauer et al., 2014
Heart RV
MCT PH and fibrosis, SDR, 2w
+ R
Bruce et al., 2015
Bleomycin, SD rats, 11d-2w
+ P and R
Katovich et al., 2016, in prep.
Kidney
ApoE def/Diabetic mice, 20w
Koulis et al., 2015
ZDF rats, 15w
Castoldi et al., 2015
SHRSP, 8w
Gelosa et al., 2009
Small vessels
SHR, 6w
Rehman et al., 2012
Large vessels
L-NAME +P
Paulis et al., 2012
Lung
MCT PH and fibrosis, SDR, 2 w
Katovich et al 2016, submitted
P = Preventive protocol (C21 administered in parallel with fibrotic agent)
R = Reversal protocol ( C21 administered after established fibrosis) 22

23. C21 COMPARED TO CURRENT REGIMENS
Product
Oral bioavailability
Rat
Reduces PH
(pre-clinical)
Safety margin rodents
(NOAEL/Effect Dose)
Troublesome adverse effects (clinic)
C21
21-27 %
YES 60
As today, none
Esbriet (Pirfenidone) Roche/Shionogi
77 % NO
1.5
Photosensitivity, nausea, rash, dyspepsia
Ofev (Nintedanib) Boehringer Ingelheim
12 %
<1
Diarrhoea, nausea, vomiting, abdominal pain
C21 has shown beneficial effects on pulmonary fibrosis and relevant pro-fibrotic mediators in animal models
C21 has shown significant benefits on pulmonary hypertension in animal models
EMA in favour of C21 with dual effect on both IPF and PH (se below)
”Indeed PH is a very severe complication of IPF and so far there is no treatment for the patients who develop PH during the course of their IPF disease. The COMP considered that the possibility of having a product that not only treats IPF but can also reduce the PH component would be a clinically relevant advantage for the patients affected by IPF, and issued a positive opinion on the orphan designation.”
Quotation from EMA orphan drug designation assessment report 23

24. BioMAP® PROFILE OF C21 IN HUMAN CELLS In-Vitro model of lung and kidney fibrosis
Key activities of C21:
Myofibroblast activation effects: decreased α-SMA, N-cadherin
Fibrosis-related matrix activities: decreased Collagen-I, Collagen-III, PAI-I; increased MMP-1, Collagen-IV
Tissue remodeling/wound healing activities: decreased EGFR; increased sVEGF
Inflammation-related activities: decreased MCP-1, VCAM-1, I-TAC, M-CSF, sIL-8; increased IL-8, sIL-6; modulated IP-10 (atypical concentration dependent effects observed for IP-10 in the REMyoF system)

25. BENCHMARK OVERLAY – C21 VS NINTEDANIB
Overlay of C21 (10 µM) and Nintedanib (1.1 µM)
There are 2 common activities that are annotated within the following system: REMyoF (Collagen I, I-TAC)
There are 15 differentiating activities (not shown) within the following systems: SAEMyoF (IP-10, MCP-1, MMP-1, MMP-9, VCAM-1, α-SMA), MyoF (Collagen IV, IL-8, MMP-1, PAI-1, TIMP-1), and REMyoF (MMP-1, sIL-6, sVEGF, uPA)
Nintedanib is a multi-angiokinase inhibitor that targets downstream mediators of bFGFR, PDGFR and VEGFR signaling. Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF).

26. BENCHMARK OVERLAY – C21 VS PIRFENIDONE
Overlay of VIC_C21 (10 µM) and Pirfenidone (1700 µM)
There are 2 common activities that are annotated within the following systems: SAEMyoF (Collagen III) and REMyoF (MCP-1)
There are 7 differentiating activities (not shown) within the following systems: SAEMyoF (IP-10, VCAM-1), MyoF (Collagen IV, IL-8, PAI-1), and REMyoF (MMP-1, sIL-6)
Pirfenidone is an anti-fibrotic compound that is approved for the treatment of idiopathic pulmonary fibrosis (IPF).

27. C21 PHASE IIa IPF PROGRAMS TO BE INITIATED
Phase IIa (1) Safety and Tolerability Study – 2 weeks
Randomized and double blind placebo controlled study in IPF patients, in collaboration with University College London and other IPF UK study group hospitals. Tentative planning:
5 active and 5 placebo
C mg QD
Primary Objectives
Safety and Tolerability
PK properties
Secondary – Explorative Investigation
Imaging PET/CT
Bronchiolar alveolar lavage (BAL): Macrophages and BAL fluid biomarkers
Serum biomarkers
Phase IIa (2) Safety and Efficacy Study – 12 weeks
Randomized and double blind placebo controlled study in IPF patients, multicenter
( patients) (C21 or placebo)
C21 in doses of (50 or 100 mg) QD
Primary outcome measures
Safety: Adverse Events
Pharmacodynamic: FVC absolute change from baseline in percent week 12
Secondary outcome measures
Pharmacodynamic Measures: Home spirometry, 6 min walk test and self-assessed quality of life 27

28. C21 IN DIABETIC NEPHROPATHY

29. C21 IN DIABETIC NEPHROPATHY
STZ-induced diabetes in ApoE-/- mice / 20 weeks oral treatment
albuminuria
TGF-beta
Koulis et a., Hypertension. 2015;65:
Zucker Diabetic Fatty Rats / 15 weeks treatment by i.p. injections
Castoldi et al., Am J Physiol Renal Physiol 307: F1123–F1131, 2014

30. C21 IN DIABETIC NEPHROPATHY
Abbreviations
Normal Control (NC)
High fat diet/STZ (35 mg/kg/ip) (HS)
High fat diet/STZ/Telmisartan (10 mg/kg/po) (HST)
High fat diet/STZ/C21 (0.3 mg/kg/po) (HSC)
High fat diet/STZ/C21/Telmisartan (HSCT)

31. STUDY DESIGN DIABETIC NEPHROPATHY
Type II diabetics with proteinurea despite controlled blood pressure and controlled blood sugar levels.
Study to be executed at Steno Clinic in Copenhagen
C21 once daily
C21 once daily
Placebo
Placebo
Principle read-out: Change in proteinurea 31

32. VICORE GOING FORWARD

33. A BROAD THERAPUTIC PLATFORM: Supported by worldwide pre-clinical research
Fibrosis
Idiopathic Pulmonary Fibrosis
Post-MI cardiac remodeling
Diabetic end organ damage
e.g. diabetic nephropathy
Hypertensive end organ damage
Scleroderma
Inflammation / Immune response
Rheumatoid Arthritis
Multiple Sclerosis
Neuromyelitis Optica
Eczema / Psoriasis
Conditions benefiting from AT2R stimulation
Cell protection and differentiation
b-cell / islet protection
Stem cell differentiation
Renal failure due to Sickle cell disease
Cardiovascular and cardio-metabolic disease
Heart failure
Post-MI cardiac function
Arterial stiffening
Metabolic syndrome
Pulmonary arterial hypertension
Neuroprotection / Neuroregeneration
Acute ischemic stroke
Spinal Cord injury
Multiple Sclerosis / NMO
Alzheimer / Dementia
Investigator sponsored Phase II studies likely to be initiated in multiple indications 33

34. FULLY FUNDED DEVELOPMENT
COMPANY STRATEGY
Gain clinical proof of concept for fibrotic disease (IPF)
Gain clinical proof of concept for metabolic disease and diabetic nephropathy
Support investigators to initiate studies to gain clinical proof of concept in other orphan drug diseases
Validate follow-on molecules for outcome indications (HF-PEF, CKD)
Evaluate license agreements for accelerated clinical development
FULLY FUNDED DEVELOPMENT
Development activities
Extension of phase I study To be reported in July 2017
CYP and Food interaction study in healthy volunteers Targeted completion Q months toxicity studies Targeted completion November 2017
Phase IIa study in Diabetic Nephropathy Targeted to start H Phase IIa studies in IPF Target to start H2 2017

35. Investor Relations nina.carlen@vicorepharma.com
Contacts:
Nina Carlén
Investor Relations
+46 (0)

36. APPENDIX

37. GRANTED AND PENDING PATENTS: C21
Composition of matter:
C USA September 2024
C EU May 2022
New Chemical Entities - USA 2037, excluding regulatory extension (Pending)
New Chemical Entities - EU 2037, excluding regulatory extension (Pending)
Method of use:
C21 in IPF - USA 2036 (published and no objections)
C21 in sickle cell disease - USA 2035 (pending)
C21 in spinal cord injury - USA 2032 (granted)
C21 in intranasal delivery for treating stroke - USA 2036 (pending)
Orphan drug designation:
IPF - USA 7yrs (granted 2017)
- EU 10yrs (granted 2016)
Spinal cord injury - USA 7yrs (pending since Oct 2016) 37

38. BOARD OF DIRECTORS Leif Darner, Chairman of the board
Leif is the owner of Darner Asset Man­age­ment AB, a con­sult­ing firm. Prior to this, he was an Exec­u­tive Direc­tor on the Board of Man­age­ment at AkzoNo­bel, respon­si­ble for Per­for­mance Coat­ings from 2008 and for Chem­i­cals from Before this, he was Man­ag­ing Direc­tor BU Marine & Pro­ tec­tive Coat­ings. Until 1999 he held var­i­ous posi­tions such as Chief Exec­u­tive North­ern Europe and Chief Exec­u­tive Pro­tec­tive Coat­ings Europe at Cour­taulds plc, UK. Prior to this , he was Man­ag­ing Direc­tor for Inter­na­tional Färg AB, Swe­den Other assignments: Board member at LKAB AB, Sweden, Flowserve Corporation, Dallas, US and I-Tech AB  
Göran Wessman, Board member
Göran has a degree from biomedicine and chemistry at Uppsala and Gothenburg. Göran has more than twenty years experience in management positions in the pharmaceutical and medical device companies as well as from the CRO business area of clinical research. Göran has held senior positions in the establishment of the Nobel Biocare and leading positions in combination with the ownership of the establishment of Boule Group and Carmel Pharma. Other assignments: Chairman of Vicore Pharma AB and Protem Wessman AB. Board member of Protem Företagsförvaltning, ITIN Holding AB and I- Tech AB.
Göran Arvidson, Board member
Göran Arvidson is CEO of Hansa Medical since April, Göran Arvidson has significant experience from the life science sector. He has been Executive Vice President and CFO of Swedish Orphan Biovitrum AB (publ), Co-founder of Biovitrum and has held senior positions with Procordia AB and Pharmacia AB.
Peter Ström, Board member
Peter Ström has an MBA from the Stockholm School of Economics. He has held senior positions in the years , including the company KabiPharmacia UK (CEO) and IMSHealth Europe (VP). Peter has since 2003 also been a director of several listed companies such as Wnt Research. Other assignments: Chairman of WntResearch AB. Board member of Stockholm Corporate Finance AB, Dentosystem Scandinavia AB, deputy member of Comtax Support Limited.
Kjell Stenberg, Board member
Kjell has extensive board experience in a large number of companies active in many industries. Other assignments: Board member of WntResearch AB, Kjell Stenberg AB and CN Stenberg AB. 38

39. SHAREHOLDERS 39 Shareholder Number of Shares Percent
Protem Wessman inkl. privat
2,521,137
15,88%
AB Pomona-Gruppen
1,705,830
10.75%
Mikael Lönn
1,405,958
8,86%
HBM Healthcare Investments (Cayman) Ltd
1,200,000
7.56%
Kjell Stenberg
1,148,478
7.24%
Eriksam Invest Aktiebolag
607,010
3.83%
Unionen
600,000
3.78%
AFA Försäkring
585,000
3.69%
Bd Medical Consulting AB
340,000
2.21%
Avanza Pension
313,255
1.97%
Per Jansson
155,097
0.98%
Others
5,286,739
33,31%
Total
15,868,504
100.00% 39

40. ADDITIONAL ASSETS: I-TECH
Product: Selektope®
Marine biocide for use in antifouling paints
Prohibit growth of barnacles on ship hulls
Largest shareholders I-Tech
Volvo Group Venture Capital AB
33.5%
ALMI Invest AB
19.0%
Vicore Pharma Holding AB
16.5%
Pomona-gruppen AB
10.0%
Estimated value of market is USD 500m
China – 30% - Selektope approved
S. Korea – 30% - Selektope approved
Japan – 20% - Selektope approved
EU – 10% - Selektope approved
US – 5% - Selektope pending approval
2 gram Selektope can replace gram of copper
First antifouling paint containing Selektope launched in Asia in 2016 by Chugoku Marine paints, one of the largest marine paint producers world-wide 40